100% SVR4 in HCV Genotype 1 Non-Cirrhotic
Treatment-Naïve or-Experienced Patients With the Combination
of ABT-493 and
ABT-530 for 8 Weeks (SURVEYOR-I)—F Poordad et al.
Source: The Liver
Conference - AASLD Late Breaker - 14
Results and Conclusions
Thirty-four patients were
enrolled in the study—56% were male, 97% white, 71% genotype 1a; 15% had
an F3 fibrosis stage at baseline, and 15% were treatment experienced. This was
the data from Part 2 of the SURVEYOR-I study, which evaluates the combination
of ABT-493 and ABT-530 of treatment of 8 weeks in non-cirrhotic patients with
genotype 1. Eighty-five percent of the patients were treatment-naïve (never
treated) and 15% had been previously treated with pegylated interferon. The
patients were treated with once-daily 300 mg ABT-493 plus120 mg ABT-530 for
eight weeks. About 1/3 of patients had
HCV RNA, or viral load was above 6,000,000 IU/mL. All 34 patients (100%)
achieved SVR4-HCV RNA negative 4 weeks post-treatment. One patient discontinued
the study prematurely at treatment week 4 due to a death – not related to the
study drug. The most common side effects were fatigue (18%), diarrhea (9%), and
cough (9%).
The Bottom Line
All of the patients achieved SVR4 – good early results and
it will be interesting to find out if eight weeks of treatment can achieve a
durable cure.
Editorial Comment
This is small early study with very encouraging results. It
will be interesting to see if similar results can be replicated in a larger
population of people across all genotypes.
Labels: Abbvie, Drugs in Development, phase 2
